Leelyn Smith LLC Boosts Stake in Zoetis Inc. $ZTS

Leelyn Smith LLC raised its position in Zoetis Inc. (NYSE:ZTS) by 3.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,450 shares of the company’s stock after purchasing an additional 881 shares during the quarter. Leelyn Smith LLC’s holdings in Zoetis were worth $3,813,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Nova Wealth Management Inc. purchased a new position in shares of Zoetis during the first quarter worth approximately $25,000. 1248 Management LLC bought a new position in shares of Zoetis during the first quarter valued at approximately $27,000. Saudi Central Bank bought a new position in shares of Zoetis during the first quarter valued at approximately $29,000. REAP Financial Group LLC boosted its stake in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares in the last quarter. Finally, Cornerstone Planning Group LLC boosted its stake in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.2%

ZTS stock opened at $146.14 on Friday. The stock has a market capitalization of $64.77 billion, a P/E ratio of 25.15, a P/E/G ratio of 2.35 and a beta of 0.90. The firm has a 50-day simple moving average of $148.18 and a 200-day simple moving average of $153.50. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $184.40.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s dividend payout ratio is currently 34.42%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Friday. UBS Group lowered their target price on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research note on Monday. Finally, Argus restated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.